USE OF A CHEMICALLY-STABILIZED CHLORITE SOLUTION FOR INHIBITING AN ANTIGEN-SPECIFIC IMMUNE RESPONSE
Methods of using a stabilized chlorite solution to inhibit antigen-specific immune responses are disclosed. The stabilized chlorite solution, when administered to a mammal in need thereof, can prevent the presentation of antigens by antigen presenting cells. The stabilized chlorite solution therefore is useful in treating, inter alia, auto-immune diseases, treating diseases caused by an inappropriate immune response, treating lymphoproliferative disease and in inhibiting rejection in transplant patients.
1 - 26 . (canceled)
27 . A method of treating allergic asthma in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of tetrachlorodecaoxygen anion complex (TCDO).
28 . The method of claim 27 , wherein the therapeutically effective amount of TCDO is in a range of from about 0.1 ml/kg to about 1.5 ml/kg body weight of the mammal.
29 . The method of claim 27 , wherein the therapeutically effective amount of TCDO is about 0.5 ml/kg body weight of the mammal.
30 . The method of claim 28 , wherein TCDO comprises a concentration of about 40 to about 80 mMol ClO 2 − per liter.
31 . The method of claim 29 , wherein TCDO comprises a concentration of about 60 mMol ClO 2 − per liter.
32 . A method of treating allergic rhinitis in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of tetrachlorodecaoxygen anion complex (TCDO).
33 . The method of claim 32 , wherein the therapeutically effective amount of TCDO is in a range of from about 0.1 ml/kg to about 1.5 ml/kg body weight of the mammal.
34 . The method of claim 32 , wherein the therapeutically effective amount of TCDO is about 0.5 ml/kg body weight of the mammal.
35 . The method of claim 33 , wherein TCDO comprises a concentration of about 40 to about 80 mMol ClO 2 − per liter.
36 . The method of claim 34 , wherein TCDO comprises a concentration of about 60 mMol ClO 2 − per liter.
37 . The method of claim 27 , wherein the composition comprising TCDO is administered to the patient as 3 to 7 daily infusions.
38 . The method of claim 27 , wherein the composition comprising TCDO is administered to the patient as 5 daily infusions.
39 . The method of claim 38 , wherein the administration is on 5 consecutive days.
40 . The method of claim 27 , wherein the composition comprising TCDO is administered to the patient for more than one treatment cycle, wherein each treatment cycle comprises 5 daily infusions of the composition followed by a rest period.
41 . The method of claim 40 , wherein the rest period is 6 months, one year or two years.
42 . The method of claim 32 , wherein the composition comprising TCDO is administered to the patient as 3 to 7 daily infusions.
43 . The method of claim 32 , wherein the composition comprising TCDO is administered to the patient as 5 daily infusions.
44 . The method of claim 43 , wherein the administration is on 5 consecutive days.
45 . The method of claim 32 , wherein the composition comprising TCDO is administered to the patient for more than one treatment cycle, wherein each treatment cycle comprises 5 daily infusions of the composition followed by a rest period.
46 . The method of claim 45 , wherein the rest period is 6 months, one year or two years.